[Long-term survival in patients with breast cancer after intra-arterial infusion chemotherapy].
Twenty two patients with locally advanced breast cancer survived for more than 5 years after intra-arterial infusion chemotherapy (IA). In this study, we compared these long-term-survivors with thirteen cases who died within 2 years. The results were as follows. (1) ER positive rate of the long-term-survivors (90%) was significantly higher than in short-term-survivors (25.0%). (2) There was no difference between the response rates of each group; 63.2% in long-term-survivors vs. 53.8% in short-term-survivors. (3) Adjuvant endocrine therapies were carried out in the former group, and their D.F.I. were considerably longer than in the latter group. (4) Common sites of recurrence in long-term-survivors were soft tissues and bones, compared with visceral in short-term-survivors. Post-recurrence survivals of the former were, also, longer than in the latter. From these results, we confirmed that preoperative IA and following adjuvant endocrine therapies induces favorable results in the treatment of hormone sensitive breast cancer.
Dept. of Surgery, Osaka National Hospital.
Y
Y
Takatsuka
Y
Y
Okamura
T
T
Kawahara
E
E
Yayoi
M
M
Kitada
K
K
Miyauchi
D001943:Breast Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000401:mortality; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000401:mortality; D011960:Receptors, Estrogen / Q000032:analysis; D012008:Recurrence; D012074:Remission Induction; D013629:Tamoxifen / Q000627:therapeutic use
D011960:Receptors, Estrogen; D013629:Tamoxifen; D004317:Doxorubicin